BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yang H, Sherman M, Su J, Chen P, Liaw Y, Iloeje UH, Chen C. Nomograms for Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Virus Infection. JCO 2010;28:2437-44. [DOI: 10.1200/jco.2009.27.4456] [Cited by in Crossref: 177] [Cited by in F6Publishing: 71] [Article Influence: 16.1] [Reference Citation Analysis]
Number Citing Articles
1 Tseng TC, Kao JH. Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: new trick of old dog. J Gastroenterol. 2013;48:13-21. [PMID: 23090000 DOI: 10.1007/s00535-012-0668-y] [Cited by in Crossref: 76] [Cited by in F6Publishing: 69] [Article Influence: 8.4] [Reference Citation Analysis]
2 Guo G, Chen X, He W, Wang H, Wang Y, Hu P, Rong Y, Fan L, Xia L. Establishment of inflammation biomarkers-based nomograms to predict prognosis of advanced colorectal cancer patients based on real world data. PLoS One 2018;13:e0208547. [PMID: 30513126 DOI: 10.1371/journal.pone.0208547] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
3 Du Y, Han X, Ding YB, Yin JH, Cao GW. Prediction and prophylaxis of hepatocellular carcinoma occurrence and postoperative recurrence in chronic hepatitis B virus-infected subjects. World J Gastroenterol 2016;22:6565-72. [PMID: 27547000 DOI: 10.3748/wjg.v22.i29.6565] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
4 Fan SS, Liao CS, Cao YD, Xiao PL, Deng T, Luo RC, Duan HX. A low serum Tat-interacting protein 30 level is a diagnostic and prognostic biomarker for hepatocellular carcinoma. Oncol Lett 2017;13:4208-14. [PMID: 28599422 DOI: 10.3892/ol.2017.6024] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
5 Xie DY, Ren ZG, Zhou J, Fan J, Gao Q. 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights. Hepatobiliary Surg Nutr. 2020;9:452-463. [PMID: 32832496 DOI: 10.21037/hbsn-20-480] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 26.0] [Reference Citation Analysis]
6 Park CH, Jeong SH, Yim HW, Kim JD, Bae SH, Choi JY, Yoon SK. Family history influences the early onset of hepatocellular carcinoma. World J Gastroenterol. 2012;18:2661-2667. [PMID: 22690075 DOI: 10.3748/wjg.v18.i21.2661] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
7 Lee HC. Noninvasive diagnostic criteria for hepatocellular carcinoma. Clin Mol Hepatol 2012;18:174-7. [PMID: 22893867 DOI: 10.3350/cmh.2012.18.2.174] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
8 Bruix J, Sherman M;  American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020-1022. [PMID: 21374666 DOI: 10.1002/hep.24199] [Cited by in Crossref: 5422] [Cited by in F6Publishing: 4923] [Article Influence: 542.2] [Reference Citation Analysis]
9 Koshiol J, Liu Z, O'Brien TR, Hildesheim A. Beasley's 1981 paper: The power of a well-designed cohort study to drive liver cancer research and prevention. Cancer Epidemiol 2018;53:195-9. [PMID: 29396075 DOI: 10.1016/j.canep.2018.01.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
10 Magalhães-Costa P, Lebre L, Peixe P, Santos S, Chagas C. Hepatocellular Carcinoma in Chronic Hepatitis B Patients on Third Generation Nucleos(t)ides Analogs: Risk Factors and Performance of a Risk Score. GE Port J Gastroenterol 2016;23:233-42. [PMID: 28868468 DOI: 10.1016/j.jpge.2016.02.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
11 Kao WY, Hwang CY, Su CW, Chang YT, Luo JC, Hou MC, Lin HC, Lee FY, Wu JC. Risk of hepato-biliary cancer after cholecystectomy: a nationwide cohort study. J Gastrointest Surg 2013;17:345-51. [PMID: 23188223 DOI: 10.1007/s11605-012-2090-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
12 Demir M, Grünewald F, Lang S, Schramm C, Bowe A, Mück V, Kütting F, Goeser T, Steffen HM. Elevated liver fibrosis index FIB-4 is not reliable for HCC risk stratification in predominantly non-Asian CHB patients. Medicine (Baltimore) 2016;95:e4602. [PMID: 27661015 DOI: 10.1097/MD.0000000000004602] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Wang Y, Wang M, Li H, Chen K, Zeng H, Bi X, Zhu Z, Jiao Y, Wang Y, Zhu J, Zhao H, Liu X, Dai C, Fan C, Zhao C, Guo D, Zhao H, Zhou J, Wang D, Wu Z, Zhao X, Cui W, Zhang X, Cai J, Chen W, Qu C. A male-ABCD algorithm for hepatocellular carcinoma risk prediction in HBsAg carriers. Chin J Cancer Res 2021;33:352-63. [PMID: 34321832 DOI: 10.21147/j.issn.1000-9604.2021.03.07] [Reference Citation Analysis]
14 Zhang S, Zhang K, Ji P, Zheng X, Jin J, Feng M, Liu P. GABPA predicts prognosis and inhibits metastasis of hepatocellular carcinoma. BMC Cancer 2017;17:380. [PMID: 28549418 DOI: 10.1186/s12885-017-3373-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
15 Shim JJ, Oh IH, Kim SB, Kim JW, Lee CK, Jang JY, Lee JS, Kim BH. Predictive Value of Antiviral Effects in the Development of Hepatocellular Carcinoma in the General Korean Population with Chronic Hepatitis B. Gut Liver 2016;10:962-8. [PMID: 27282260 DOI: 10.5009/gnl15426] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
16 Nishikawa H, Nishijima N, Enomoto H, Sakamoto A, Nasu A, Komekado H, Nishimura T, Kita R, Kimura T, Iijima H, Nishiguchi S, Osaki Y. Comparison of FIB-4 index and aspartate aminotransferase to platelet ratio index on carcinogenesis in chronic hepatitis B treated with entecavir. J Cancer. 2017;8:152-161. [PMID: 28243319 DOI: 10.7150/jca.16523] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
17 Dogan S, Gurakar A. Liver Transplantation Update: 2014. Euroasian J Hepatogastroenterol 2015;5:98-106. [PMID: 29201702 DOI: 10.5005/jp-journals-10018-1144] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
18 Ramachandran J. Surveillance for hepatocellular carcinoma. J Clin Exp Hepatol. 2014;4:S50-S56. [PMID: 25755611 DOI: 10.1016/j.jceh.2014.03.050] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
19 An J, Lee HC. Surveillance for hepatocellular carcinoma in chronic hepatitis B virus infection: for whom. Hepat Oncol. 2015;2:225-229. [PMID: 30191004 DOI: 10.2217/hep.15.17] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
20 Niederau C. Chronic hepatitis B in 2014: great therapeutic progress, large diagnostic deficit. World J Gastroenterol 2014;20:11595-617. [PMID: 25206267 DOI: 10.3748/wjg.v20.i33.11595] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
21 Lin YJ, Lee MH, Yang HI, Jen CL, You SL, Wang LY, Lu SN, Liu J, Chen CJ. Predictability of liver-related seromarkers for the risk of hepatocellular carcinoma in chronic hepatitis B patients. PLoS One. 2013;8:e61448. [PMID: 23613855 DOI: 10.1371/journal.pone.0061448] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
22 Wen CP, Lin J, Yang YC, Tsai MK, Tsao CK, Etzel C, Huang M, Hsu CY, Ye Y, Mishra L. Hepatocellular carcinoma risk prediction model for the general population: the predictive power of transaminases. J Natl Cancer Inst. 2012;104:1599-1611. [PMID: 23073549 DOI: 10.1093/jnci/djs372] [Cited by in Crossref: 64] [Cited by in F6Publishing: 57] [Article Influence: 7.1] [Reference Citation Analysis]
23 Zhang H, Zhu J, Xi L, Xu C, Wu A. Validation of the Toronto hepatocellular carcinoma risk index for patients with cirrhosis in China: a retrospective cohort study.World J Surg Oncol. 2019;17:75. [PMID: 31039803 DOI: 10.1186/s12957-019-1619-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
24 Rangwala F, Omenetti A, Diehl AM. Cancer stem cells: repair gone awry? J Oncol. 2011;2011:465343. [PMID: 21188169 DOI: 10.1155/2011/465343] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
25 Liu X, Zhou J, Zhou N, Zhu J, Feng Y, Miao X. SYNJ2BP inhibits tumor growth and metastasis by activating DLL4 pathway in hepatocellular carcinoma. J Exp Clin Cancer Res 2016;35:115. [PMID: 27440153 DOI: 10.1186/s13046-016-0385-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
26 Yang Y, Gao J, Tan YT, Li HL, Wang J, Ma X, Zheng W, Shu XO, Xiang YB. Individual and combined effects of hepatitis B surface antigen level and viral load on liver cancer risk. J Gastroenterol Hepatol 2018;33:1131-7. [PMID: 29065440 DOI: 10.1111/jgh.14032] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
27 El Hadad S, Alakilli S, Rabah S, Sabir J. Sequence analysis of sub-genotype D hepatitis B surface antigens isolated from Jeddah, Saudi Arabia. Saudi J Biol Sci 2018;25:838-47. [PMID: 29740253 DOI: 10.1016/j.sjbs.2016.03.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
28 Croagh CM, Desmond PV, Bell SJ. Genotypes and viral variants in chronic hepatitis B: A review of epidemiology and clinical relevance. World J Hepatol. 2015;7:289-303. [PMID: 25848459 DOI: 10.4254/wjh.v7.i3.289] [Cited by in Crossref: 68] [Cited by in F6Publishing: 61] [Article Influence: 11.3] [Reference Citation Analysis]
29 Galun D, Basaric D, Zuvela M, Bulajic P, Bogdanovic A, Bidzic N, Milicevic M. Hepatocellular carcinoma: From clinical practice to evidence-based treatment protocols. World J Hepatol. 2015;7:2274-2291. [PMID: 26380652 DOI: 10.4254/wjh.v7.i20.2274] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 4.8] [Reference Citation Analysis]
30 Tanwar S, Dusheiko G. Is There Any Value to Hepatitis B Virus Genotype Analysis? Curr Gastroenterol Rep 2012;14:37-46. [DOI: 10.1007/s11894-011-0233-5] [Cited by in Crossref: 55] [Cited by in F6Publishing: 45] [Article Influence: 5.5] [Reference Citation Analysis]
31 Kao JH. Molecular epidemiology of hepatitis B virus. Korean J Intern Med 2011;26:255-61. [PMID: 22016585 DOI: 10.3904/kjim.2011.26.3.255] [Cited by in Crossref: 36] [Cited by in F6Publishing: 24] [Article Influence: 3.6] [Reference Citation Analysis]
32 Aghoram R, Cai P, Dickinson JA. Alpha-foetoprotein and/or liver ultrasonography for screening of hepatocellular carcinoma in patients with chronic hepatitis B. Cochrane Database Syst Rev 2012;:CD002799. [PMID: 22972059 DOI: 10.1002/14651858.CD002799.pub2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 31] [Article Influence: 2.3] [Reference Citation Analysis]
33 Chang KC, Wu YY, Hung CH, Lu SN, Lee CM, Chiu KW, Tsai MC, Tseng PL, Huang CM, Cho CL, Chen HH, Hu TH. Clinical-guide risk prediction of hepatocellular carcinoma development in chronic hepatitis C patients after interferon-based therapy. Br J Cancer 2013;109:2481-8. [PMID: 24084770 DOI: 10.1038/bjc.2013.564] [Cited by in Crossref: 49] [Cited by in F6Publishing: 40] [Article Influence: 6.1] [Reference Citation Analysis]
34 Marshall A, Lukk M, Kutter C, Davies S, Alexander G, Odom DT. Global gene expression profiling reveals SPINK1 as a potential hepatocellular carcinoma marker. PLoS One. 2013;8:e59459. [PMID: 23527199 DOI: 10.1371/journal.pone.0059459] [Cited by in Crossref: 48] [Cited by in F6Publishing: 42] [Article Influence: 6.0] [Reference Citation Analysis]
35 Bruix J, Han KH, Gores G, Llovet JM, Mazzaferro V. Liver cancer: Approaching a personalized care. J Hepatol 2015;62:S144-56. [PMID: 25920083 DOI: 10.1016/j.jhep.2015.02.007] [Cited by in Crossref: 136] [Cited by in F6Publishing: 125] [Article Influence: 27.2] [Reference Citation Analysis]
36 Lok AS. Personalized treatment of hepatitis B. Clin Mol Hepatol. 2015;21:1-6. [PMID: 25834795 DOI: 10.3350/cmh.2015.21.1.1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
37 Cheng R, Xu J, Tan N, Luo H, Pan J, Xu X. Predictive Nomograms for Clinical Outcomes in Hepatitis B-Related Cirrhosis Patients Receiving Antiviral Therapy. Infect Drug Resist 2021;14:2707-19. [PMID: 34290509 DOI: 10.2147/IDR.S316026] [Reference Citation Analysis]
38 Dhanasekaran R, Limaye A, Cabrera R. Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics. Hepat Med. 2012;4:19-37. [PMID: 24367230 DOI: 10.2147/hmer.s16316] [Cited by in Crossref: 39] [Cited by in F6Publishing: 122] [Article Influence: 4.3] [Reference Citation Analysis]
39 Liaw YF, Kao JH, Piratvisuth T, Chan HL, Chien RN, Liu CJ, Gane E, Locarnini S, Lim SG, Han KH. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012;6:531-561. [PMID: 26201469 DOI: 10.1007/s12072-012-9365-4] [Cited by in Crossref: 695] [Cited by in F6Publishing: 645] [Article Influence: 77.2] [Reference Citation Analysis]
40 Ni X, Li D, Dai S, Pan H, Sun H, Ao J, Chen L, Kong H. Development and Evaluation of Nomograms to Predict the Cancer-Specific Mortality and Overall Mortality of Patients with Hepatocellular Carcinoma. Biomed Res Int 2021;2021:1658403. [PMID: 33860031 DOI: 10.1155/2021/1658403] [Reference Citation Analysis]
41 Ma X, Yang Y, Tu H, Gao J, Tan YT, Zheng JL, Bray F, Xiang YB. Risk prediction models for hepatocellular carcinoma in different populations. Chin J Cancer Res. 2016;28:150-160. [PMID: 27199512 DOI: 10.21147/j.issn.1000-9604.2016.02.02] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
42 Hsu A, Lai CL, Yuen MF. Update on the Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Virus Infection. Curr Hepat Rep. 2011;10:106-111. [PMID: 21654908 DOI: 10.1007/s11901-011-0094-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
43 Vivarelli M, Montalti R, Risaliti A. Multimodal treatment of hepatocellular carcinoma on cirrhosis: an update. World J Gastroenterol. 2013;19:7316-7326. [PMID: 24259963 DOI: 10.3748/wjg.v19.i42.7316] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 24] [Article Influence: 3.6] [Reference Citation Analysis]
44 Liu J, Hu HH, Lee MH, Korenaga M, Jen CL, Batrla-Utermann R, Lu SN, Wang LY, Mizokami M, Chen CJ, Yang HI. Serum Levels of M2BPGi as Short-Term Predictors of Hepatocellular Carcinoma in Untreated Chronic Hepatitis B Patients. Sci Rep. 2017;7:14352. [PMID: 29085039 DOI: 10.1038/s41598-017-14747-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
45 Chen JL, Lin XJ, Zhou Q, Shi M, Li SP, Lao XM. Association of HBV DNA replication with antiviral treatment outcomes in the patients with early-stage HBV-related hepatocellular carcinoma undergoing curative resection. Chin J Cancer 2016;35:28. [PMID: 26992891 DOI: 10.1186/s40880-016-0089-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 3.4] [Reference Citation Analysis]
46 Kennedy PTF, Litwin S, Dolman GE, Bertoletti A, Mason WS. Immune Tolerant Chronic Hepatitis B: The Unrecognized Risks. Viruses 2017;9:E96. [PMID: 28468285 DOI: 10.3390/v9050096] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 7.8] [Reference Citation Analysis]
47 Zhang H, Yan XL, Guo XX, Shi MJ, Lu YY, Zhou QM, Chen QL, Hu YY, Xu LM, Huang S, Su SB. MiR-27a as a predictor for the activation of hepatic stellate cells and hepatitis B virus-induced liver cirrhosis. Oncotarget. 2018;9:1075-1090. [PMID: 29416678 DOI: 10.18632/oncotarget.23262] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
48 Song IH, Kim SM, Choo YK. Risk prediction of hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy. World J Gastroenterol 2013;19:8867-72. [PMID: 24379609 DOI: 10.3748/wjg.v19.i47.8867] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
49 Sachar Y, Brahmania M, Dhanasekaran R, Congly SE. Screening for Hepatocellular Carcinoma in Patients with Hepatitis B. Viruses 2021;13:1318. [PMID: 34372524 DOI: 10.3390/v13071318] [Reference Citation Analysis]
50 Kubota N, Fujiwara N, Hoshida Y. Clinical and Molecular Prediction of Hepatocellular Carcinoma Risk. J Clin Med 2020;9:E3843. [PMID: 33256232 DOI: 10.3390/jcm9123843] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
51 Burak KW, Kneteman NM. An evidence-based multidisciplinary approach to the management of hepatocellular carcinoma (HCC): the Alberta HCC algorithm. Can J Gastroenterol 2010;24:643-50. [PMID: 21157578 DOI: 10.1155/2010/410574] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
52 Lee HW, Ahn SH. Prediction models of hepatocellular carcinoma development in chronic hepatitis B patients. World J Gastroenterol. 2016;22:8314-8321. [PMID: 27729738 DOI: 10.3748/wjg.v22.i37.8314] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 28] [Article Influence: 7.3] [Reference Citation Analysis]
53 Huang YH, Liang KH, Chien RN, Hu TH, Lin KH, Hsu CW, Lin CL, Pan TL, Ke PY, Yeh CT. A Circulating MicroRNA Signature Capable of Assessing the Risk of Hepatocellular Carcinoma in Cirrhotic Patients. Sci Rep. 2017;7:523. [PMID: 28364124 DOI: 10.1038/s41598-017-00631-9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
54 Sato M, Morimoto K, Kajihara S, Tateishi R, Shiina S, Koike K, Yatomi Y. Machine-learning Approach for the Development of a Novel Predictive Model for the Diagnosis of Hepatocellular Carcinoma. Sci Rep. 2019;9:7704. [PMID: 31147560 DOI: 10.1038/s41598-019-44022-8] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 13.0] [Reference Citation Analysis]
55 Sherman M. How to improve HCC surveillance outcomes. JHEP Rep 2019;1:460-7. [PMID: 32039398 DOI: 10.1016/j.jhepr.2019.10.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
56 Chen CJ, Lee MH, Liu J, Yang HI. Hepatocellular carcinoma risk scores: ready to use in 2015? Hepat Oncol 2015;2:1-4. [PMID: 30190979 DOI: 10.2217/hep.14.32] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
57 Liang KH, Zhang P, Lin CL, Wang SC, Hu TH, Yeh CT, Su GL. Morphomic Signatures Derived from Computed Tomography Predict Hepatocellular Carcinoma Occurrence in Cirrhotic Patients. Dig Dis Sci 2020;65:2130-9. [PMID: 31677071 DOI: 10.1007/s10620-019-05915-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
58 Tsai CH, Muo CH, Hung CH, Lin TL, Wang TI, Fong YC, Hsu HC. Disorder-related risk factors for revision total hip arthroplasty after hip hemiarthroplasty in displaced femoral neck fracture patients: a nationwide population-based cohort study. J Orthop Surg Res 2016;11:66. [PMID: 27277082 DOI: 10.1186/s13018-016-0400-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
59 Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020-1022. [PMID: 21374666 DOI: 10.1002/hep.24199.] [Reference Citation Analysis]
60 Wu T, Ma XA, Wang GQ, Li Q, Li MJ, Guo JY, Liang X, Ruan ZP, Tian T, Nan KJ, Liu LN, Guo H. ABO blood type correlates with survival in hepatocellular carcinoma following hepatectomy. Sci Rep 2017;7:4412. [PMID: 28667286 DOI: 10.1038/s41598-017-04046-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
61 Fujiwara N, Friedman SL, Goossens N, Hoshida Y. Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine. J Hepatol 2018;68:526-49. [PMID: 28989095 DOI: 10.1016/j.jhep.2017.09.016] [Cited by in Crossref: 198] [Cited by in F6Publishing: 177] [Article Influence: 49.5] [Reference Citation Analysis]
62 Nishikawa H, Nishijima N, Enomoto H, Sakamoto A, Nasu A, Komekado H, Nishimura T, Kita R, Kimura T, Iijima H, Nishiguchi S, Osaki Y. A predictive model for carcinogenesis in patients with chronic hepatitis B undergoing entecavir therapy and its validation. Medicine (Baltimore) 2016;95:e4832. [PMID: 27603400 DOI: 10.1097/MD.0000000000004832] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
63 Wu HC, Yang HI, Wang Q, Chen CJ, Santella RM. Plasma DNA methylation marker and hepatocellular carcinoma risk prediction model for the general population. Carcinogenesis 2017;38:1021-8. [PMID: 28981677 DOI: 10.1093/carcin/bgx078] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
64 Yang JD, Roberts LR. Hepatocellular carcinoma: A global view. Nat Rev Gastroenterol Hepatol 2010;7:448-58. [PMID: 20628345 DOI: 10.1038/nrgastro.2010.100] [Cited by in Crossref: 810] [Cited by in F6Publishing: 764] [Article Influence: 73.6] [Reference Citation Analysis]
65 Coffin CS, Fung SK, Ma MM; Canadian Association for the Study of the Liver. Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines. Can J Gastroenterol 2012;26:917-38. [PMID: 23248795 DOI: 10.1155/2012/506819] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 4.8] [Reference Citation Analysis]
66 Hsu A, Lai CL, Yuen MF. Update on the Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Virus Infection. Curr Hepat Rep. 2011;10:106-111. [PMID: 21654908 DOI: 10.1007/s11901-011-0094-] [Reference Citation Analysis]
67 Yang HI, Lee MH, Liu J, Chen CJ. Risk calculators for hepatocellular carcinoma in patients affected with chronic hepatitis B in Asia. World J Gastroenterol 2014;20:6244-51. [PMID: 24876745 DOI: 10.3748/wjg.v20.i20.6244] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
68 Kwong JC, Ratnasingham S, Campitelli MA, Daneman N, Deeks SL, Manuel DG, Allen VG, Bayoumi AM, Fazil A, Fisman DN, Gershon AS, Gournis E, Heathcote EJ, Jamieson FB, Jha P, Khan KM, Majowicz SE, Mazzulli T, McGeer AJ, Muller MP, Raut A, Rea E, Remis RS, Shahin R, Wright AJ, Zagorski B, Crowcroft NS. The impact of infection on population health: results of the Ontario burden of infectious diseases study. PLoS One 2012;7:e44103. [PMID: 22962601 DOI: 10.1371/journal.pone.0044103] [Cited by in Crossref: 69] [Cited by in F6Publishing: 69] [Article Influence: 7.7] [Reference Citation Analysis]
69 Imedio ER, Beveridge RD, Urtasun JA, Campos GB, Estellés DL, Esparcia MF, Daroqui JC, Huerta ÁS, Ortiz AG, Salcedo JM. Safety and efficacy of sorafenib in the treatment of advanced hepatocellular carcinoma: a single center experience. Med Oncol 2014;31:948. [PMID: 24740650 DOI: 10.1007/s12032-014-0948-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
70 Ji M, Liu Z, Chang ET, Yu X, Wu B, Deng L, Feng Q, Wei K, Liang X, Lian S, Quan W, Wang P, Du Y, Liang Z, Xia S, Lin H, Li F, Cheng W, Chen W, Yuan Y, Ye W. Mass screening for liver cancer: results from a demonstration screening project in Zhongshan City, China. Sci Rep 2018;8:12787. [PMID: 30143694 DOI: 10.1038/s41598-018-31119-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
71 Lok AS, Zoulim F, Dusheiko G, Ghany MG. Hepatitis B cure: From discovery to regulatory approval. Hepatology. 2017;66:1296-1313. [PMID: 28762522 DOI: 10.1002/hep.29323] [Cited by in Crossref: 129] [Cited by in F6Publishing: 120] [Article Influence: 32.3] [Reference Citation Analysis]